$131 Million is the total value of OUP Management Co., LLC's 16 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q1 2022 |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-04
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Centessa Pharmaceuticals plc | 8 | Q3 2023 | 42.7% |
Aerovate Therapeutics Inc. | 8 | Q3 2023 | 28.9% |
PMV Pharmaceuticals, Inc. | 8 | Q3 2023 | 19.4% |
Cyteir Therapeutics, Inc. | 8 | Q3 2023 | 15.7% |
Vor Biopharma Inc. | 8 | Q3 2023 | 4.1% |
Precision BioSciences, Inc. | 8 | Q3 2023 | 3.7% |
Graphite Bio | 8 | Q3 2023 | 2.3% |
eFFECTOR Therapeutics, Inc. | 8 | Q3 2023 | 3.8% |
Selecta Biosciences, Inc. | 8 | Q3 2023 | 2.4% |
Spero Therapeutics, Inc. | 8 | Q3 2023 | 1.8% |
View OUP Management Co., LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2023-11-09 |
13F-HR | 2023-08-07 |
13F-HR | 2023-04-24 |
13F-HR | 2023-02-02 |
13F-HR | 2022-11-01 |
13F-HR | 2022-07-19 |
13F-HR | 2022-05-04 |
13F-HR | 2022-02-03 |
View OUP Management Co., LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.